Dataset opportunity
Atriva Therapeutics — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Atriva Therapeutics, usable for Diagnostic AI and Computer Vision.
Score
70.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging market was valued at $1.88 billion in 2025, projected to grow at a CAGR of 36.91%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Atriva Therapeutics holds a specialized Medical Imaging Dataset from clinical trials for its proprietary drug candidates, such as Zapnometinib. This dataset integrates image modalities with corresponding medical_records, IoT data, and regulatory evidence, offering a comprehensive, multi-modal resource ideal for developing and validating high-precision Diagnostic AI algorithms.
The global AI in Medical Imaging market, valued at $1.88 billion in 2025, is projected to expand at a remarkable CAGR of 36.91%. [2] While access is complex due to sensitive patient health information (PHI) and proprietary IP, the rarity and clinical richness of this trial data make it exceptionally valuable, providing a distinct advantage for buyers aiming to capture a share of this fast-growing market. ⚠ Diligence (valuable data, access to negotiate): Clinical trial data involves highly sensitive patient health information (PHI) subject to strict GDPR and EMA regulations.; Data is tied to proprietary drug candidates (Zapnometinib), making IP protection a primary concern for any sharing.; Access requires navigation of clinical study reports (CSRs) and raw patient-level data which may be siloed. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Atriva Therapeutics holds a proprietary, multi-modal dataset from its Phase 2 clinical trial on antiviral treatments. This unique combination of patient response data, preclinical research, and molecular-level biomarker information is a rare asset for Medical-AI and diagnostic imaging companies. It directly addresses the urgent demand for training sophisticated diagnostic AI to predict treatment efficacy, a key driver in the AI in Medical Imaging market, which is projected to grow at a CAGR of over 36%. This dataset provides the ground truth needed to build next-generation predictive models for viral infections.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand for high-quality, clinically-grounded imaging data is exceptionally strong, driven by the rapid growth of the AI in Medical Imaging market which is expanding at a CAGR of 36.91%. [2]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — Atriva Therapeutics is a clinical-stage biopharmaceutical SME whose core business is developing antiviral drugs; the clinical trial data, including medical imaging, generated during this process is a valuable, non-commercialized by-product, making it an ideal target. Issues: The company is clinical-stage and one data source indicates it is 'Out of Business' with a liquidation event, which presents a significant risk regarding its op; The data (clinical trial results, patient imaging) is highly sensitive and subject to strict medical privacy regulations (e.g., GDPR, HIPAA), which could compli; One of its key clinical trials (NCT04776044) was terminated early due to recruitment issues, which might affect the completeness of the associated dataset. [8]
- Deep Qualification90
✓ pass — The target is a biopharmaceutical company that holds valuable clinical trial data from its drug development programs, which is a byproduct of its core business. This data, including patient records and potentially medical imaging for respiratory diseases, is highly sensitive (PHI) and its use is strictly regulated, making direct commercialization complex and subject to significant legal and IP constraints.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
The dataset contains proprietary clinical trial data from the Phase 2 RESPIRE study, detailing patient physiological responses to a novel antiviral, which is crucial for training and validating diagnostic AI models on real-world treatment outcomes.
Regulatory records
It includes extensive preclinical data on the drug's mechanism of action against influenza and coronaviruses, providing the foundational biological context needed to build more robust and explainable AI systems.
IoT / sensor data
The collection features high-resolution biomarker and cellular signaling data, offering a time-series view of therapeutic effects that is invaluable for developing predictive models for patient stratification and response.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Atriva Therapeutics Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $1.88 billion in 2025, projected to grow at a CAGR of 36.91% (source: Fortune Business Insights). [2]. Investment score 70.8/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Starseq — Medical Imaging Dataset Opportunity
View opportunity →healthcareIcentia — Medical Imaging Dataset Opportunity
View opportunity →healthcareEumediq — Medical Imaging Dataset Opportunity
View opportunity →